Cancer trial tests if less treatment is just as good
NCT ID NCT07373990
Summary
This study is testing if a shorter treatment schedule with the immunotherapy drug tislelizumab, combined with standard chemotherapy and radiation, works as well as the standard, longer schedule for people with advanced nasopharyngeal cancer. It will involve about 418 adults to see if the shorter course is just as effective at keeping the cancer from coming back. The main goal is to see if patients do just as well with fewer treatment cycles, which could mean fewer side effects and lower costs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.